Improve Human Health to Preserve Patients’ Dignity

Leading new drug development for genitourinary tumors & other related diseases

Highlights

Cancer Foundation of China and Asieris Pharmaceuticals Forge Strategic Partnership for Cervical Cancer Prevention and Control

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Treatment Areas

Bladder Cancer

Lack of oral therapy for non-muscle invasive bladder cancer (NMIBC) patients with improved patient compliance and less adverse effects from intravesical administration.

Precancerous Cervical Dysplasia

In urgent need of safe and effective options for patients with cervical precancerous lesions, currently treated by traditional surgical methods.

Global Partnership

News & Updates

November 6, 2024

Cancer Foundation of China and Asieris Pharmaceuticals Forge Strategic Partnership for Cervical Cancer Prevention and Control

November 5, 2024

Asieris Showcases World’s 1st Product for Non-Invasive Treatment of Precancerous Cervical Lesions at its CIIE Debut

October 24, 2024

Asieris Received FDA IND Approval for a Novel USP1 Inhibitor for the Treatment of Advanced Solid Tumors

October 22, 2024

Asieris Pharmaceuticals and ECUST’s School of Chemistry and Molecular Engineering Forge Strategic Partnership on Photodynamic Platforms

October 21, 2024

Asieris Pharmaceuticals Appoints Richard Zhao as Senior Vice President of Business Development

September 29, 2024

Asieris Unveils Results for the First Time at 2024 CSCO Conference the Subgroup Analysis of Pathological Regression Rate and HPV Clearance Rate at 6 Months in Different Age Groups of the Non-Surgical Treatment for Cervical HSIL Product APL-1702 Clinical Study

Technology Platform